Floatz Rating
B57/100
Confidence
Indicative
Sponsor
Apurano Pharmaceuticals GmbH
Modality
UNKNOWN
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
45Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06071936CT.gov Efficacy and Tolerability of AP707 in Patients With Chronic Pain Due to Traumatic or Post-operative Peripheral Neuropathy | — | Unknown | — | — | — |
NCT06071949CT.gov Efficacy and Tolerability of AP707 in Patients With Chronic Pain Due to Central Neuropathy of Any Genesis | — | Unknown | — | — | — |
NCT06071962CT.gov Long Term Efficacy and Tolerability of AP707 in Patients With Chronic Back Pain | — | Unknown | — | — | — |
NCT06071975CT.gov Long Term Efficacy and Tolerability of AP707 in Patients With Chronic Pain Due to Diabetic Polyneuropathy | — | Unknown | — | — | — |
NCT06071988CT.gov Long Term Efficacy and Tolerability of AP707 in Patients With Chronic Pain Due to Traumatic or Post-operative Peripheral Neuropathy | — | Unknown | — | — | — |
NCT06072001CT.gov Long Term Efficacy and Tolerability of AP707 in Patients With Chronic Pain Due to Central Neuropathy of Any Genesis | — | Unknown | — | — | — |
NCT06072560CT.gov Efficacy and Tolerability of AP707 in Patients With Chronic Back Pain | — | Unknown | — | — | — |
NCT06072573CT.gov Efficacy and Tolerability of AP707 in Patients With Chronic Pain Due to Diabetic Polyneuropathy | — | Unknown | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Chronic Pain Syndrome
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Adezunap (this asset) | Apurano Pharmaceuticals GmbH | P3 | B · 57 |
| (±)-Tramadol | EMS | P4 | BBB |
| Methadone | Cari Health Inc. | P4 | BBB |
| Lidocaine | National and Kapodistrian University of Athens | P4 | BBB |
| Fentanyl | Aga Khan University | P4 | BBB |
| (±)-2-(O-Chlorophenyl)-2-(Methylamino)Cyclohexanone | Stanford University | P4 | BBB |
| Nepenthe | Bursa City Hospital | P4 | BBB |
| Oxycodone | Mayo Clinic | P4 | BBB |
| Pregabalin | Federico II University | P4 | BBB |
+42 more in the Chronic Pain Syndrome cohort
Other indications for Adezunap
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Vertebral Column Disorder | — | P3 | B · 60 |
| Diabetic Neuropathy | — | P3 | B · 60 |
| Diabetic Polyneuropathy | — | P3 | B · 60 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Adezunap in Chronic Pain Syndrome. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/adezunap-chronic-pain-syndrome
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →